title: Targeting prandial hyperglycemia: how important is it and how best to do this?
abstract: The contribution of postprandial glucose (PPG) excursions to the overall hyperglycemia of patients with type 2 diabetes depends on the degree of diabetic control. PPG is a major contributor in patients with hemoglobin A(1c) (HbA(1c)) levels below 7.3%, whereas the contribution of fasting plasma glucose (FPG) is preponderant in poorly controlled patients. In addition, the loss of postprandial glycemic control precedes stepwise degradation of fasting with worsening diabetes. As a consequence, monitoring after meals is particularly important in patients with HbA(1c) levels ranging from 6.5% to 8%. In such patients, targeting PPG below 140 mg/dL should be one of the main objectives to achieve HbA(1c) less than 6.5%. The new hypoglycemic agents, such as the glucagon-like peptide-1 analogues and the dipeptidyl peptidase-4 inhibitors which have a gluco-dependent insulinotropic effect, should normally reinforce our therapeutic armamentarium for achieving the glycemic targets that should include the three components of the glucose triad: HbA(1c), FPG, and PPG.
authors.affiliation: Laboratory of Human Nutrition, University Institute of Clinical Research, 641 Avenue du Doyen Giraud, 34093 Montpellier Cedex 5, France. louis.monnier@inserm.fr
authors.forename: Louis
authors.initials: L
authors.lastname: Monnier
authors.forename: Claude
authors.initials: C
authors.lastname: Colette
mesh_terms: D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy / Q000503:physiopathology*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D019518:Postprandial Period / Q000502:physiology*
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human
references.citation: N Engl J Med. 1993 Sep 30;329(14):977-86
references.pmid: 8366922
references.citation: JAMA. 2003 Jul 23;290(4):486-94
references.pmid: 12876091
references.citation: Diabetes Metab. 2004 Apr;30(2):113-9
references.pmid: 15223983
references.citation: Eur J Clin Invest. 2000 Aug;30 Suppl 2:3-11
references.pmid: 10975048
references.citation: N Engl J Med. 2007 Feb 1;356(5):437-40
references.pmid: 17267901
references.citation: Int J Clin Pharmacol Ther. 2003 Oct;41(10):421-40
references.pmid: 14703948
references.citation: Endocr Pract. 2006 Jan-Feb;12 Suppl 1:6-12
references.pmid: 16627372
references.citation: Diabetes Care. 2003 Jan;26 Suppl 1:S5-20
references.pmid: 12502614
references.citation: Diabetes Care. 2007 Feb;30(2):263-9
references.pmid: 17259492
references.citation: Diabet Med. 1998 Apr;15(4):290-6
references.pmid: 9585393
references.citation: N Engl J Med. 1988 May 12;318(19):1231-9
references.pmid: 3283554
references.citation: Diabetes. 1996 Aug;45(8):1044-50
references.pmid: 8690150
references.citation: Diabetes Metab. 2006 Sep;32 Spec No2:2S11-6
references.pmid: 17375401
references.citation: N Engl J Med. 1992 Sep 3;327(10):707-13
references.pmid: 1495524
references.citation: Diabetes Care. 2002 Apr;25(4):737-41
references.pmid: 11919134
references.citation: Diabetes Care. 1997 Dec;20(12):1822-6
references.pmid: 9405900
references.citation: Arch Intern Med. 2004 Oct 25;164(19):2090-5
references.pmid: 15505121
references.citation: Diabetes. 2008 Apr;57(4):995-1001
references.pmid: 18223010
references.citation: Diabetologia. 2006 May;49(5):846-54
references.pmid: 16532323
references.citation: Drugs. 2001;61(11):1625-60
references.pmid: 11577798
references.citation: Diabetologia. 1995 Dec;38(12):1378-88
references.pmid: 8786010
references.citation: Lancet. 1999 Aug 21;354(9179):617-21
references.pmid: 10466661
references.citation: Nature. 2001 Dec 13;414(6865):813-20
references.pmid: 11742414
references.citation: Diabetes Care. 2008 Feb;31 Suppl 2:S150-4
references.pmid: 18227477
references.citation: Circulation. 2004 Jul 13;110(2):214-9
references.pmid: 15197140
references.citation: Diabetes Care. 2002 Feb;25(2):275-8
references.pmid: 11815495
references.citation: Stroke. 2004 May;35(5):1073-8
references.pmid: 15073402
references.citation: N Engl J Med. 2005 Jan 13;352(2):174-83
references.pmid: 15647580
references.citation: N Engl J Med. 1984 Mar 22;310(12):746-50
references.pmid: 6366551
references.citation: Diabetes Care. 2003 Mar;26(3):881-5
references.pmid: 12610053
references.citation: Horm Metab Res. 2007 Sep;39(9):683-6
references.pmid: 17846977
references.citation: Diabetes Care. 2001 Dec;24(12):2023-9
references.pmid: 11723077
references.citation: Diabetes Metab. 2008 Jun;34(3):207-16
references.pmid: 18511324
references.citation: Diabetes. 2005 Jan;54(1):1-7
references.pmid: 15616004
references.citation: Diabetes. 1988 Jun;37(6):667-87
references.pmid: 3289989
references.citation: Diabetologia. 2001 Dec;44(12):2107-14
references.pmid: 11793012
references.citation: Diabetes. 1995 Nov;44(11):1249-58
references.pmid: 7589820
references.citation: BMJ. 2000 Aug 12;321(7258):405-12
references.pmid: 10938048
references.citation: Diabetes Care. 2006 Aug;29(8):1963-72
references.pmid: 16873813
references.citation: Diabetes Care. 1999 Feb;22(2):233-40
references.pmid: 10333939
references.citation: Diabetologia. 1996 Dec;39(12):1577-83
references.pmid: 8960845
references.citation: Eur J Clin Invest. 2006 Apr;36(4):231-5
references.pmid: 16620284
references.citation: J Clin Endocrinol Metab. 2006 Mar;91(3):813-9
references.pmid: 16352690